

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

**SUPPLEMENTAL INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet 1

of

2

Application Number	10/692,105
Filing Date	October 23, 2003
First Named Inventor	Bradley
Art Unit	1655
Examiner Name	Michele C. Flood
Attorney Docket Number	B185 T1015.1 (MSC 8009.5)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² <i>(if known)</i>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	P1	US-4,499,073	02-12-1985	Tenold	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ⁴ Number ⁴ Kind Code ⁵ <i>(if known)</i>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
	F1	WO 97/15572	05-01-1997	Janssen Pharmaceutica N.V.		
	F2	GB 2 090 599 A	07-14-1982	Novo Industri A/S		

Examiner Signature	/Michele Flood/	Date Considered	12/06/2008
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 27 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		<i>Complete if Known</i>	
		Application Number	10/692,105
		Filing Date	October 23, 2003
		First Named Inventor	Bradley
		Art Unit	1655
Examiner Name Michele C. Flood			
Sheet	2	of	2
		Attorney Docket Number	B185 T1015.1 (MSC 8009.5)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials* Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.	T ²
D1	Alkjaersig, N., <i>et al.</i> , "The Activation of Human Plasminogen," <i>J. Biol. Chem.</i> , 233(1): 81-85 (1958).	
D2	Alkjaersig, N., <i>et al.</i> , "The Mechanism of Clot Dissolution by Plasmin," <i>J. Clin. Invest.</i> , 38(7): 1086-1095 (1959).	
D3	Becker, Gary J., "Local Thrombolytic Therapy: Bridging the 'Generation Gap,'" <i>Am. J. Roentgenol.</i> , 140(2): 403-405 (1983).	
D4	Holmberg, L., <i>et al.</i> , "Purification of Urokinase by Affinity Chromatography," <i>Biochim. Biophys. Acta.</i> , 445: 215-222 (1976).	
D5	Mathey D.G., <i>et al.</i> , "Intravenous Urokinase in Acute Myocardial Infarction," <i>Am. J. Cardiol.</i> , 55: 878-882 (1985).	
D6	Novokhatny, V., <i>et al.</i> , "Thrombolytic potency of acid-stabilized plasmin: superiority over tissue-type plasminogen activator in an <i>in vitro</i> model of catheter-assisted thrombolysis," <i>J. Thromb. Haemost.</i> , 1: 1034-1041 (2003).	
D7	Petitpretz, P., <i>et al.</i> , "Effects of a single bolus of urokinase in patients with life-threatening pulmonary emboli: a descriptive trial," <i>Circulation</i> , 70(5): 861-866 (1984).	
D8	Seifert, V., <i>et al.</i> , "Efficacy of Single Intracisternal Bolus Injection of Recombinant Tissue Plasminogen Activator to Prevent Delayed Cerebral Vasospasm after Experimental Subarachnoid Hemorrhage," <i>Neurosurgery</i> , 25(4): 590-598 (1989).	
D9	Wiman, B., and Per Wallén, "Activation of Human Plasminogen by an Insoluble Derivative of Urokinase Structural Changes of Plasminogen in the course of Activation to Plasmin and Demonstration of a Possible Intermediate Compound," <i>Eur. J. Biochem.</i> , 36(1): 25-31 (1973).	
D10	EXTENDED EUROPEAN SEARCH REPORT (EP 1 956 082 A1, dated 10 July 2008).	
Examiner Signature	/Michele Flood/	Date Considered 12/06/2008

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.F./